
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Karen J. McConnell, Pharm.D., FCCP, BCPS, talks about the role that products like PCSK9 will play in the future.
Karen J. McConnell, Pharm.D., FCCP, BCPS, clinical pharmacy specialist in cardiology at the Kaiser Permanente of Colorado and associate professor at the Skaggs School of Pharmacy (University of Colorado) talks about the role that products like PCSK9 will play in the future.
This video was recorded at APhA’s Annual Meeting and Exposition in March 2015.






